SLC5A2 and diabetic kidney disease: Beyond diabetic patients, SGLT2 inhibitors are now recognized as first-line agents in the treatment of heart failure and diabetic nephropathy and are even considered safe for use in immunosuppressed kidney transplant recipients [15].